"Are you saying that dox does not work?"
PW is saying, as he keeps maintaining, that DOX is not being released at all by AVA6K and that any of the efficacy results being show are in line with the random chance that some tumours shrink of their own accord.. |
Well, Fieldhouse and Cheshire ... genuinely surprised at that market reaction. Well done, at least for now. |
This worm will turn and evolve into a gazelle or something similar. Perhaps 2025 is the year. |
We are all ‘doomed’, ‘all doomed’. The plague returns ! |
Whitey: ..."because it (the drug) does not work". My understanding is that AVA6000 is not a drug per se but a delivery system that allows standard dox to work with significantly reduced side effects. Are you saying that dox does not work?
The RNS seemed very positive to me. LTH and not day trading Avacta, so happy to await developments. |
I'm afraid this is pretty much a re-hash of results that have been drip fed out since 19th September 2023 (likely done now to help with the next death spiral loan conversion in a few days).
Still only a very few confirmed significant responses and I note that they now focus on a subset of just the 10 patients with SGC dosed at 250 mg/m2 and above, not out of the total of 57 patients thus far, I suspect this is to make it look better.
The first patient was dosed on 11th August 2021 so that's now three and a half years and all we can conclude after all that time is that it's safer at higher doses and thus possibly a bit more effective than standard dox. So when's the Phase II, it should have started in 2024? Apart from AVA6000 all they have now are the back to the drawing board pre-clinical candidates. |
"Based on this favorable efficacy and safety data observed in the Phase 1a trial, Avacta has initiated three Phase 1b expansion cohorts"
Going into the fifth year now at Phase 1. The only thing that is guaranteed is that the drug is 100% safe at all dosage levels and that's because it does not work. |
Thanks to:
"So, to summarize: even in extremely sick patients with advanced stage SGC, and who have very little (if any) treatment options available remaining to them, AVA6000 has prevented disease progression in 90% of cases.
In contrast, in treatment-naive patients with earlier stage SGC, there currently exists no standard-of-care.
Results should improve significantly for AVA6000, when used as a first-line therapy for those patients with earlier stage SGC.
It's now patently obvious (at least to me!) that AVA6000 is on for accelerated approval for the treatment of SGC." |
Surely at this stage it’s all about proof that the delivery vehicle works. Adding warheads and identification of the most efficient combination is just a matter of time now. |
Looks positive to me .
If I was unfortunate enough to be diagnosed with SGC I would certainly want to be treated with AVa6000
Where there is life,there is hope ! |
Raj looking to buy back in again. Been AWOL since last punt and loss. Should see a hefty fall this morning - belt up, strap in, enjoy the ride. I.m certainly not seeing this as majorly positive. Delivery works, but MOTD not worked out yet?! Better, newer,warheads reqd obviously. It.s a gulp day. Not great for current sufferers ...poor souls. |
Also, patients are continuing to see results even when off the drug. What's not to like?! |
There is no standard treatment for SGC in metastatic settings. This particular cancer is extremely difficult to treat. Plus all the patients would have been heavily pre-treated with chemo. For them to achieve any sort of positive response on this trial is superb. |
 Christina Coughlin MD, PhD, CEO of Avacta, commented,
"These data highlight the transformative potential of our pre|CISION® peptide drug conjugates in expanding the efficacy of highly potent therapeutics and support our growing optimism in this program.
"Salivary gland cancer is a devastating disease with no established standard of care treatment options. AVA6000 demonstrated a clinically meaningful tumor shrinkage in SGC patients, highlighting its potential as an important new treatment option for patients with SGC and other solid tumors.
"We look forward to continuing to work with our investigators and the broader community to explore its potential in SGC and other cancers. We are thrilled to begin enrollment in the expansion cohorts, and this part of the trial will also be conducted in less heavily pretreated patients which will allow us to better understand the potential of AVA6000 in these disease settings with high unmet need."
These results demonstrate preliminary evidence of durable antitumor activity in patients with SGC, supported by ongoing RECIST1 responses (both partial and minor responses) in a disease setting with no standard of care. SGC accounts for 6-8% of head and neck cancers in the US, with approximately 2,500 cases diagnosed in the US each year2. There is no standard of care for SGC once patients have developed distant metastasis, with a five year survival rate of approximately 43%. |
But if the side effects are mild then that means better patient conditions Better results are expected |
That data does not read great to me!
· Among 10 patients treated at the dose of 250 mg/m2 and above, five patients demonstrate tumor shrinkage (one partial and four minor responses)
One partial response and 4 'minor' only???
Whoops |
Funny as ...Nasdaq ...ho ho ho. |
AVACTA announced the appointment of Brian Hahn as Chief Financial Officer (CFO). He was previously CFO and Senior Vice President of GlycoMimetics, Inc., where he led the company’s 2014 initial public offering (IPO) on Nasdaq.
Courtesy of Zak Mir |
Conviboyz we R ere wo oh,wo oh ...sing along ...soon be Easter |
The Yanks have taken over ! |
Nasdaq IPO on the cards |
We.re caught in a trap ... suspicious minds ...Elvis has left San Fran. Clam chowder anyone? |
'Oops there goes gravity'...M n M. |
You want to see how it should be done. |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
